Hematology: Bortezomib in newly diagnosed multiple myeloma

Nature Reviews Clinical Oncology

Volumn 6, Issue 5, 2009, Pages 255-256

  Berenson, James R ^a  

^a INSTITUTE FOR MYELOMA AND BONE CANCER RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; MELPHALAN; PREDNISONE; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; PROTEINASE INHIBITOR; PYRAZINE DERIVATIVE;

ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; DISEASE COURSE; FOLLOW UP; NOTE; PATHOLOGY; SURVIVAL RATE; TIME; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; CLINICAL TRIALS, PHASE III AS TOPIC; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; FOLLOW-UP STUDIES; HUMANS; MELPHALAN; MULTICENTER STUDIES AS TOPIC; MULTIPLE MYELOMA; PREDNISONE; PROTEASE INHIBITORS; PYRAZINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME;

EID: 67651220672     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2009.47     Document Type: Article

References (10)

1. Myeloma Trialists Collaborative Group. Combination chemotherapy versus melphalan plus prednisolone as treatment for multiple myeloma: An overview of 6633 patients from 27 randomised trials. J. Clin. Oncol. 16, 3832-3842 (1998).
2. Ma, M. H. et al. The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin. Cancer Res. 9, 1136-1144 (2003).
3. Berenson, J. R. et al. Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma. J. Clin. Oncol. 24, 937-944 (2006).
4. San Miguel, J. F. et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N. Engl. J. Med. 359 906-917 (2008).
5. Reece, D. E. et al. Phase I-II trial of bortezomib plus oral cyclophosphamide and prednisone in relapsed and refractory multiple myeloma. J. Clin. Oncol. 26, 4777-4783 (2008).
6. Pönisch, W. et al. Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and prednisone - a randomized phase III study of the East German Study Group of Hematology and Oncology (OsHO). J. Cancer Res. Clin. Oncol. 132, 205-212 (2006).
7. Orlowski, R. Z. et al. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: Combination therapy improves time to progression. J. Clin. Oncol. 25, 3892-3901 (2007).
8. Palumbo, A. et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: Randomised controlled trial. Lancet 367, 825-831 (2006).
9. Berenson, J. R. et al. A phase I study of samarium lexidronam/ bortezomib combination therapy for the treatment of relapsed or refractory multiple myeloma. Clin. Cancer Res. 15, 1069-1075 (2009).
10. Berenson, J. R. et al. Efficacy and safety of melphalan, arsenic trioxide and ascorbic acid combination therapy in patients with relapsed or refractory multiple myeloma: A prospective, multicentre, phase II, single-arm study. Br. J. Haematol. 135, 174-183 (2006).